Full disclosure - Nothing less will do

Journal of Investigative Dermatology

Volumn 127, Issue 8, 2007, Pages 1831-1833

  Williams, Hywel C ^a  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL PROTOCOL; CONFLICT OF INTEREST; DERMATOLOGY; DRUG INDUSTRY; DRUG RESEARCH; EDITORIAL; HEALTH CARE POLICY; MEDICAL DECISION MAKING; MELANOMA; PATIENT CARE; PRIORITY JOURNAL; RESEARCH; SCIENTIFIC LITERATURE; SKIN DISEASE;

CONFLICT OF INTEREST; DERMATOLOGY; DISCLOSURE; DRUG INDUSTRY; HUMANS;

EID: 34447545541     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/sj.jid.5700931     Document Type: Editorial

References (23)

1. Bartus CL, Katz KA (2006) Advertising in dermatology journals: journals' and journal editors' policies, practices, and attitudes. J Am Acad Dermatol 55:116-22
2. Caplan AL (2007) Halfway there: the struggle to manage conflicts of interest. J Clin Invest 117:509-10
3. Chalmers I (2006) Why fair tests are needed: a brief history. Evid Based Med 11:67-8
4. Chan AW, Altman DG (2005) Identifying outcome reporting bias in randomised trials on PubMed: review of publications and survey of authors. BMJ 330:753-9
5. Dellavalle RP, Lundahl K, Freeman SR, Schilling LM (2007) Journals should set a new standard in transparency. Nature 445:364
6. Goldsmith LA (2006) Conflict of interest and the JID. J Invest Dermatol 126:2147-8
7. Gotzsche PC, Hrobjartsson A, Johansen HK, Haahr MT, Altman DG, Chan AW (2007) Ghost authorship in industry-initiated randomised trials. PLoS Med Jan 16;4(1): e19
8. House of Commons Health Committee (2005) The Influence of the Pharmaceutical Industry. The Stationery Office: London. 〈http://www. publications.parliament.uk/pa/cm200405/cmselect/cmhealth/42/42.pdf〉 Accessed 26 April 2007
9. Katz KA (2005) AMEVIVE's advertisements: problematic? Arch Dermatol 141:1602-4
10. Krumholz HM, Ross JS, Presler AH, Egilman DS (2007) What have we learnt from Vioxx? BMJ 334:120-3
11. Kuehn BM (2005) Pharmaceutical industry funding for residencies sparks controversy. JAMA 293:1572-80
12. Melander H, Ahlqvist-Rastad J, Meijer G, Beermann B (2003) Evidence b(i)ased medicine - selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. BMJ 326:1171-3
13. Neill US, Thompson CB, Feldmann M, Kelley WN (2007) A new JCI conflict-of-interest policy. J Clin Invest 117:506-8
14. Perlis CS, Harwood M, Perlis RH (2005) Extent and impact of industry sponsorship conflicts of interest in dermatology research. J Am Acad Dermatol 52:967-71
15. Prendergast MM, Abramovits W, Boguniewicz M, Lebwohl M, Tokar M, Tong KB (2004) Look beyond financial conflicts of interest in evaluating industry-academia collaborations in burden-of-illness and outcomes research studies in dermatology. J Invest Dermatol 123:452-4
16. Rees J (2007) The nature of clinical evidence: floating currencies rather than gold standards. J Invest Dermatol 127:499-500
17. Smith R (2006) Conflicts of interest: how money clouds objectivity. In: The Trouble with Medical Journals. Royal Society of Medicine Press: London pp. 125-38
18. Stossel TP (1999). Do strict regulations governing academic-industrial relationships in biomedical research and education make sense? Curr Opin Hematol 6:363-4
19. Stossel TP (2005) Regulating academic-industry research relationships: solving problems or stifling progress? N Engl J Med 355:1060-5
20. Stossel TP (2007) Conflicts of interest in dermatology: more than skin deep? J Invest Dermatol 127:1829-30
21. von Elm E, Poglia G, Walder B, Tramer MR (2004) Different patterns of duplicate publication: an analysis of articles used in systematic reviews. JAMA 291:974-80
22. Williams HC (2003) Evening primrose oil for atopic dermatitis. BMJ 327:1358-9
23. Williams HC, Naldi L, Paul C, Vahlquist A, Schroter S, Jobling R (2006) Conflicts of interest in dermatology. Acta Derm Venereol 86:485-97